Literature DB >> 15309515

Prevention of colorectal cancer through the use of COX-2 selective inhibitors.

Richard M Peek1.   

Abstract

Colorectal cancer is a major cause of morbidity and mortality accounting for an estimated 550,000 deaths annually worldwide. Colonic neoplasia develops in a stepwise fashion progressing from normal mucosa to adenomatous polyps to carcinoma, a process that takes years, thereby providing a prime opportunity for intervention. Although early detection by fecal occult blood testing and sigmoidoscopy can decrease the risk of cancer-related death by 20-30%, most persons never undergo appropriate screening. Population-based studies have previously determined that long-term ingestion of aspirin or other nonsteroidal antiinflammatory drugs (NSAIDs) leads to a 40-50% reduction in mortality. from colorectal cancer. These observational studies fueled subsequent mechanistic investigations that led to the identification of a molecular target, cyclooxygenase-2 (COX-2). COX-2 has tumor-promoting properties. Expression of COX-2 is virtually undetectable in normal intestinal mucosa, but is increased in approximately 50% of colonic adenomas and in 90% of colorectal carcinomas. Experimental studies in mice have revealed that genetic ablation or pharmacologic inhibition of COX-2 attenuates the number and size of intestinal polyps that develop in animals harboring a mutation in Apc, which confers an increased risk for intestinal neoplasia. Recent clinical studies using specific COX-2 inhibitors have shown that these compounds can: (1) reduce intestinal polyp burden in patients with familial adenomatous polyposis; (2) prevent the occurrence and/ or recurrence of colorectal adenomas and cancers; and (3) negatively regulate angiogenesis in colorectal cancer liver metastases. Compared to nonselective NSAIDs, COX-2 specific inhibitors cause substantially fewer gastrointestinal side effects. These findings indicate that a widely used and relatively safe class of drugs may represent a viable and effective anticancer strategy for a disease that causes over a half-million deaths per year.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15309515     DOI: 10.1007/s00280-004-0887-x

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  10 in total

Review 1.  Role of retinoids in the prevention and treatment of colorectal cancer.

Authors:  Catherine C Applegate; Michelle A Lane
Journal:  World J Gastrointest Oncol       Date:  2015-10-15

2.  Effects of cyclooxygenase-2 inhibition on serum and tumor gastrins and expression of apoptosis-related proteins in colorectal cancer.

Authors:  Peter C Konturek; Kazimierz Rembiasz; Grzegorz Burnat; Stanisław J Konturek; Marcin Tusinela; Władysław Bielanski; Jens Rehfeld; Danuta Karcz; Eckhart Hahn
Journal:  Dig Dis Sci       Date:  2006-04       Impact factor: 3.199

Review 3.  Cruciferous Vegetables, Isothiocyanates, and Bladder Cancer Prevention.

Authors:  Besma Abbaoui; Christopher R Lucas; Ken M Riedl; Steven K Clinton; Amir Mortazavi
Journal:  Mol Nutr Food Res       Date:  2018-08-29       Impact factor: 5.914

4.  Interaction of ibuprofen and other structurally related NSAIDs with the sodium-coupled monocarboxylate transporter SMCT1 (SLC5A8).

Authors:  Shirou Itagaki; Elangovan Gopal; Lina Zhuang; You-Jun Fei; Seiji Miyauchi; Puttur D Prasad; Vadivel Ganapathy
Journal:  Pharm Res       Date:  2006-06-01       Impact factor: 4.580

5.  Nitric Oxide (NO) and Cyclooxygenase-2 (COX-2) Cross-Talk in Co-Cultures of Tumor Spheroids with Normal Cells.

Authors:  Roman Paduch; Martyna Kandefer-Szerszeń
Journal:  Cancer Microenviron       Date:  2011-02-22

6.  Whole blood viscosity issues VI: Association with blood salicylate level and gastrointestinal bleeding.

Authors:  Ezekiel Uba Nwose; Nathan Cann
Journal:  N Am J Med Sci       Date:  2010-10

7.  Tetrandrine suppresses adhesion, migration and invasion of human colon cancer SW620 cells via inhibition of nuclear factor-κB, matrix metalloproteinase-2 and matrix metalloproteinase-9 signaling pathways.

Authors:  Ta-Kuo Juan; Kuo-Ching Liu; Chao-Lin Kuo; Mei-Due Yang; Yung-Lin Chu; Jiun-Long Yang; Ping-Ping Wu; Yi-Ping Huang; Kuang-Chi Lai; Jing-Gung Chung
Journal:  Oncol Lett       Date:  2018-03-16       Impact factor: 2.967

8.  Emodin Inhibits Inflammation, Carcinogenesis, and Cancer Progression in the AOM/DSS Model of Colitis-Associated Intestinal Tumorigenesis.

Authors:  Yunsha Zhang; Weiling Pu; Mélanie Bousquenaud; Sarah Cattin; Jelena Zaric; Li-Kang Sun; Curzio Rüegg
Journal:  Front Oncol       Date:  2021-01-08       Impact factor: 6.244

9.  Dandelion root extract affects colorectal cancer proliferation and survival through the activation of multiple death signalling pathways.

Authors:  Pamela Ovadje; Saleem Ammar; Jose-Antonio Guerrero; John Thor Arnason; Siyaram Pandey
Journal:  Oncotarget       Date:  2016-11-08

10.  Conception, synthesis, and characterization of a rofecoxib-combretastatin hybrid drug with potent cyclooxygenase-2 (COX-2) inhibiting and microtubule disrupting activities in colon cancer cell culture and xenograft models.

Authors:  Surendra R Punganuru; Hanumantha Rao Madala; Constantinos M Mikelis; Anshuman Dixit; Viswanath Arutla; Kalkunte S Srivenugopal
Journal:  Oncotarget       Date:  2018-05-25
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.